Home / Blog / State availability

Can't Get Compounded Tirzepatide in Your State? Why It Happens and Exactly What to Do (2026)

The licensing machinery behind "we don't serve your state"

Three separate licenses have to align for a legal shipment to reach your door, and a failure of any one produces the same unhelpful error message. The pharmacy must be licensed in its home state and hold a nonresident pharmacy license in your state — fifty separate applications, fees, inspections in some cases, and renewal calendars, which is why even excellent pharmacies rarely cover all fifty. The prescriber must be licensed to practice in your state, which large telehealth medical groups solve with multi-state clinician networks but smaller ones sometimes can't. And the telehealth encounter itself must satisfy your state's rules about establishing a patient relationship remotely. Providers compress all this into "not available in your state," but the distinction matters enormously for what you do next: a licensure gap is a shopping problem with a same-week solution, while an actual state restriction — much rarer — is a different conversation. The pattern to internalize: the medication is legal in your state; this particular pipeline to it isn't.

Why some states are chronically thin — and why maps change monthly

State boards of pharmacy are not interchangeable. Some process nonresident applications in weeks; others take many months, require in-person inspections, impose sterile-compounding requirements beyond federal baselines, or add state-specific rules for shipping temperature-sensitive sterile preparations. California's board is the one users mention most — its nonresident requirements are demanding enough that plenty of 503A pharmacies simply haven't completed them, so Californians see "unavailable" screens from providers that serve the other forty-nine. A handful of other states cycle on and off the difficult list as rules and pharmacy rosters change. Two practical consequences follow. First, availability is a pairing fact — "Provider X in State Y" — not a fact about you, which is why the fix is switching pairings. Second, maps genuinely change: pharmacies gain and lose licenses, providers switch pharmacy partners, and a state that was closed in March can be open in August. That churn is exactly why state coverage is one of the nineteen fields in our dataset schema, why it carries a verification date, and why several providers' maps — including our partner NexLife's — sit in the open-items queue until we can confirm them: a stale state map is worse than none.

The playbook when you hit the wall

Confirm the wall is real. Re-enter your state at intake carefully — mis-set location fields cause phantom denials — and ask support the precise question: "Is this a pharmacy licensure limit, and do you have plans to add my state?" The quality of that answer is itself a provider signal. Shop the pairing, not the category. Work down the ledger by price and check state coverage at each rung: Eden's roughly fifty-state reported footprint via its in-house pharmacy is the widest we track; Henry, MEDVi, Mochi, Hims, and the rest each cover large-but-different maps; and the flagship comparison plus the provider universe give you the ordered list to walk. Price the brand detour honestly. LillyDirect ships FDA-approved Zepbound vials nationwide at $299–449 — no compounding licensure involved — and for some people in thin states, a few months of brand while a preferred provider adds their state is the cleanest bridge; eligible Medicare beneficiaries have the $50 Bridge regardless of compounding maps, and the Foundayo pill at $149–349 ships nationally too. Ask about the waitlist. Providers expanding into a state often take intake early and notify at launch; that costs you nothing and occasionally beats switching. Never take the gray-market exit. A no-prescription or overseas site "solves" your state problem by removing the pharmacy, the license, and the law all at once — the exact triad protecting you — and adds international cold-chain failure on top; the full case is in the safety risk map.

Moving between states mid-program: the wrinkle nobody warns you about

Your program's legality is anchored to where you are, so a move can break a working setup: the pharmacy may not be licensed in your new state, and your prescriber may not be either. Handle it like a planned provider switch rather than an emergency — tell your current provider the move date early and ask directly whether both pharmacy and clinician cover the new state; if not, run the overlap discipline from the access guide: complete the new provider's intake before you move, have the first shipment confirmed to the new address, and only then wind down the old program. Expect the new pharmacy's vial to be a different concentration, which means your syringe units change even though your dose doesn't — the one-minute recalculation ritual in the dosage chart exists for exactly this moment. Snowbirds and split-state households should ask one more question at intake: which address the pharmacy can ship to, and whether both states are on its license — some programs handle dual addresses gracefully, others not at all, and it's a five-minute question that prevents a February scramble.

How to read a provider's state claims like an auditor

"Available in all 50 states" is a marketing sentence until it's specific. The auditor's questions: Which pharmacy dispenses, and what's its license number in my state? (Check it yourself — every state board runs a public license lookup, and the NABP's verification tools cover most.) Is the fifty-state claim about the pharmacy or about a network of pharmacies? Multi-pharmacy networks are legitimate but mean your vial's source — and concentration — can vary. Does "available" include my medication and format, or just some products? Coverage sometimes differs between semaglutide and tirzepatide, or between injectable and other formats. A provider that answers all three crisply has told you something about everything else it does; one that treats the questions as unusual has too. In our ledger, unverifiable state claims cap a provider's status at reported no matter what its homepage says — the same standard, applied to partners and non-partners alike.

The support-call script: ten questions that settle it in one conversation

Before paying any provider in a thin-coverage state, spend ten minutes with their support chat and this script. One: "Which pharmacy will dispense my prescription, by name?" Two: "What is that pharmacy's license number in my state?" — then verify it yourself in the state board's public lookup before continuing. Three: "Is your prescriber network licensed in my state, and will a named clinician review my intake?" Four: "If I'm eligible, what concentration will my vials be, in mg/mL?" — you'll need it for the units math anyway, and hesitation here is diagnostic. Five: "Does your state coverage differ between semaglutide and tirzepatide, or between formats?" Six: "If your pharmacy loses or lacks my state, do you have a second licensed pharmacy, and would my concentration change?" Seven: "What happens to my subscription if I move states mid-plan?" Eight: "Is the price I see the true recurring price in my state — any state-specific fees, shipping differences, or dose-based increases?" Nine: "What are your cancellation terms, in writing?" Ten: "When did you last confirm your state map?" A provider that answers all ten crisply in one session has effectively passed the audit; one that escalates, deflects, or answers "we're available everywhere" to question two has failed it, whatever the homepage says. Log the answers — they're your receipts if the story changes at checkout.

How the ledger tracks state coverage — and what "verified" will mean

State coverage is one of the nineteen fields every program carries in our machine-readable dataset, and it's held to the same three-tier standard as pricing: operator for maps a provider asserts (including our partner NexLife, whose state map is currently an open verification item on its fact sheet), reported for maps corroborated by third-party trackers or user reports, and verified reserved for maps we've confirmed against the actual pharmacy license in the actual state board database, with the lookup date recorded. The monthly re-verification queue prioritizes exactly the states where readers report walls, and coverage changes land in the public corrections log with dataset version bumps — because a comparison site's stale "ships to your state" claim costs you a wasted intake and a week of delay, which is precisely the failure mode this ledger exists to prevent. If a provider's map contradicts your checkout experience, that's a correction: report it and both the page and the dataset change within 48 hours.

Frequently asked questions

Sources: State board of pharmacy nonresident licensure requirements and public license lookups; NABP verification resources; federal 503A framework (patient-specific compounding); provider state-coverage claims recorded with verification dates in the dataset. Catalog: /sources/.